TY  - JOUR
AU  - Vergnenegre, Alain
AU  - Massuti, Bartomeu
AU  - de Marinis, Filippo
AU  - Carcereny, Enric
AU  - Felip, Enriqueta
AU  - Do, Pascal
AU  - Sanchez, Jose Miguel
AU  - Paz-Arez, Luis
AU  - Chouaid, Christos
AU  - Rosell, Rafael
AU  - Spanish Lung Cancer Group, Italian Association of Thoracic Oncology, and French Lung Cancer Group
PY  - 2016
DO  - 10.1016/j.jtho.2016.02.004
UR  - http://hdl.handle.net/10668/9852
T2  - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
AB  - The cost-effectiveness of first-line tyrosine kinase inhibitor therapy in epidermal growth factor receptor gene (EGFR)-mutated advanced-stage non-small cell lung cancer (NSCLC) is poorly documented. We therefore conducted a cost-effectiveness analysis...
LA  - en
KW  - EGFR-mutated patients
KW  - Economical analysis
KW  - Non–small cell lung cancer
KW  - Tyrosine kinase inhibitors
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Cost-Benefit Analysis
KW  - ErbB Receptors
KW  - Erlotinib Hydrochloride
KW  - Europe
KW  - Humans
KW  - Lung Neoplasms
KW  - Mutation
KW  - Neoplasm Staging
KW  - Prognosis
KW  - Protein Kinase Inhibitors
KW  - Quality-Adjusted Life Years
TI  - Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC.
TY  - research article
VL  - 11
ER  -